vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Piedmont Realty Trust, Inc. (PDM). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $143.3M, roughly 1.3× Piedmont Realty Trust, Inc.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -31.4%, a 30.7% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs 0.4%). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 0.0%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Piedmont Realty Trust, Inc. is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality office properties primarily located in high-growth metropolitan areas across the United States. It serves corporate tenants across multiple industry sectors including technology, professional services, and healthcare, and pursues stable long-term returns for stakeholders via strategic property management and portfolio optimization.
AVNS vs PDM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $143.3M |
| Net Profit | $-1.3M | $-45.0M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | — |
| Net Margin | -0.7% | -31.4% |
| Revenue YoY | 0.7% | 0.4% |
| Net Profit YoY | 99.7% | -27.9% |
| EPS (diluted) | $-0.02 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $143.3M | ||
| Q4 25 | $180.9M | $142.9M | ||
| Q3 25 | $177.8M | $139.2M | ||
| Q2 25 | $175.0M | $140.3M | ||
| Q1 25 | $167.5M | $142.7M | ||
| Q4 24 | $179.6M | $143.2M | ||
| Q3 24 | $170.4M | $139.3M | ||
| Q2 24 | $171.7M | $143.3M |
| Q1 26 | — | $-45.0M | ||
| Q4 25 | $-1.3M | $-43.2M | ||
| Q3 25 | $-1.4M | $-13.5M | ||
| Q2 25 | $-76.8M | $-16.8M | ||
| Q1 25 | $6.6M | $-10.1M | ||
| Q4 24 | $-397.3M | $-30.0M | ||
| Q3 24 | $4.3M | $-11.5M | ||
| Q2 24 | $1.8M | $-9.8M |
| Q1 26 | — | — | ||
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | -42.6% | — | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | -233.0% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | 3.7% | — |
| Q1 26 | — | -31.4% | ||
| Q4 25 | -0.7% | -30.3% | ||
| Q3 25 | -0.8% | -9.7% | ||
| Q2 25 | -43.9% | -12.0% | ||
| Q1 25 | 3.9% | -7.1% | ||
| Q4 24 | -221.2% | -20.9% | ||
| Q3 24 | 2.5% | -8.3% | ||
| Q2 24 | 1.0% | -6.8% |
| Q1 26 | — | $-0.10 | ||
| Q4 25 | $-0.02 | $-0.34 | ||
| Q3 25 | $-0.03 | $-0.11 | ||
| Q2 25 | $-1.66 | $-0.14 | ||
| Q1 25 | $0.14 | $-0.08 | ||
| Q4 24 | $-8.64 | $-0.25 | ||
| Q3 24 | $0.09 | $-0.09 | ||
| Q2 24 | $0.04 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $2.3M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $1.5B |
| Total Assets | $1.1B | $4.0B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $2.3M | ||
| Q4 25 | $89.8M | $731.0K | ||
| Q3 25 | $70.5M | $3.0M | ||
| Q2 25 | $90.3M | $3.3M | ||
| Q1 25 | $97.0M | $2.9M | ||
| Q4 24 | $107.7M | $109.6M | ||
| Q3 24 | $89.0M | $133.6M | ||
| Q2 24 | $92.2M | $138.5M |
| Q1 26 | — | — | ||
| Q4 25 | $90.3M | $2.2B | ||
| Q3 25 | $93.4M | $2.2B | ||
| Q2 25 | $95.7M | $2.2B | ||
| Q1 25 | $98.0M | $2.2B | ||
| Q4 24 | $125.3M | $2.2B | ||
| Q3 24 | $152.6M | $2.2B | ||
| Q2 24 | $164.9M | $2.2B |
| Q1 26 | — | $1.5B | ||
| Q4 25 | $778.2M | $1.5B | ||
| Q3 25 | $778.0M | $1.5B | ||
| Q2 25 | $776.3M | $1.5B | ||
| Q1 25 | $839.4M | $1.6B | ||
| Q4 24 | $828.5M | $1.6B | ||
| Q3 24 | $1.2B | $1.6B | ||
| Q2 24 | $1.2B | $1.7B |
| Q1 26 | — | $4.0B | ||
| Q4 25 | $1.1B | $4.0B | ||
| Q3 25 | $1.1B | $4.0B | ||
| Q2 25 | $1.0B | $4.0B | ||
| Q1 25 | $1.1B | $4.0B | ||
| Q4 24 | $1.2B | $4.1B | ||
| Q3 24 | $1.7B | $4.1B | ||
| Q2 24 | $1.7B | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.12× | 1.49× | ||
| Q3 25 | 0.12× | 1.43× | ||
| Q2 25 | 0.12× | 1.41× | ||
| Q1 25 | 0.12× | 1.40× | ||
| Q4 24 | 0.15× | 1.40× | ||
| Q3 24 | 0.12× | 1.36× | ||
| Q2 24 | 0.13× | 1.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | — |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | 110.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.2M | $140.6M | ||
| Q3 25 | $14.0M | $35.8M | ||
| Q2 25 | $6.8M | $50.1M | ||
| Q1 25 | $25.7M | $3.7M | ||
| Q4 24 | $57.9M | $198.1M | ||
| Q3 24 | $23.0M | $42.9M | ||
| Q2 24 | $27.8M | $66.8M |
| Q1 26 | — | — | ||
| Q4 25 | $21.3M | — | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $-4.2M | — | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $53.1M | — | ||
| Q3 24 | $20.0M | — | ||
| Q2 24 | $21.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | -2.4% | — | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 29.6% | — | ||
| Q3 24 | 11.7% | — | ||
| Q2 24 | 12.8% | — |
| Q1 26 | — | 110.3% | ||
| Q4 25 | 3.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 6.3% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 3.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
PDM
Segment breakdown not available.
